Anti-MAGE-A1 (scfv) h(NKG2D-2B4-DAP10-CD3z) CAR-NK92 Cell Pool (XS-1125-LX60)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This CAR-NK92 product targets the cancer-testis antigen MAGE-A1 with a scFv and h(NKG2D-2B4-DAP10-CD3z) signaling. It is for RUO in research on tumor-specific antigen targeting and solid tumors.

  Add to Cart

CAR Information

  • Target
  • MAGE-A1
  • Common Name
  • Magea1
  • Full Name
  • Melanoma-associated antigen 1
  • Introduction
  • A Cancer-Testis Antigen (CTA), normally only expressed in the testis. Its aberrant expression in melanoma and lung cancer makes it a potential target for TCR and CAR cell therapies.
  • Alternative Names
  • Melanoma-associated antigen 1
  • Targeting Diseases
  • Cancer
  • Antibody Clone
  • scfv
  • scFv Host Species
  • Human
  • Hinge
  • CD8 or Others design, such as CD28
  • TM
  • CD8 or Others design, such as CD28
  • Marker
  • GFP or N/A
  • Discription of Signaling Cassetes
  • The h(NKG2D-2B4-DAP10-CD3z) chimeric antigen receptor (CAR) is a specialized construct designed to enhance the anti-tumor activity of engineered immune cells, particularly Natural Killer (NK) cells or T cells, by combining multiple signaling domains. The design is a third-generation CAR incorporating an antigen-binding domain derived from the native NKG2D receptor and multiple intracellular signaling domains.
  • Receptor Construction
  • h(NKG2D-2B4-DAP10-CD3z)
    Other receptor construction also avilable, such as NKG2D-2B4-CD3z format; CD28-41BB-CD3z format, and so on.
  • Target Species
  • Human
  • Cell Type
  • NK92
  • Cell Background
  • The NK92 cell line is an immortalized human natural killer (NK) cell line used extensively in preclinical research and clinical trials for cancer immunotherapy, particularly in the development of chimeric antigen receptor (CAR)-NK cell therapies.
  • CAR Positive Rate
  • >70%
  • CAR Expression
  • Positive
  • Mycoplasma Testing
  • Negative
  • Handling Notes
  • Frozen cells should be thawed immediately upon receipt and grown according to handling procedure to ensure cell viability and proper assay performance.
    Note: Do not freeze the cells upon receipt as it may result in irreversible damage to the cell line.
    Disclaimer: We cannot guarantee cell viability if the cells are not thawed immediately upon receipt and grown according to handling procedure.
  • Safety Consideration
  • Biosafety Level 1
  • Restriction
  • Research use only
  • Size
  • 2 million cells*2 vials
  • Storage
  • Frozen cells should be stored in a liquid nitrogen tank (-150°C~-190°C) for long term.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-MAGE-A1 (scfv) h(NKG2D-2B4-DAP10-CD3z) CAR-NK92 Cell Pool (XS-1125-LX60). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.